WFRF:(Baecklund Johan)
Search: WFRF:(Baecklund Johan) > Mortality rates in ...
- 40 of 47
- Previous record
- Next record
- To hitlist
Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors : drug-specific comparisons in the Swedish Biologics Register.
-
- Simard, Julia F (author)
- Karolinska Institutet
-
- Neovius, Martin (author)
- Karolinska Institutet
-
- Askling, Johan (author)
- Karolinska Institutet
- show more...
- show less...
- (creator_code:org_t)
- 2012-10-27
- 2012
- English.
- In: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 64:11
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- OBJECTIVE: To determine whether the differences in the modes of action and safety profiles of individual tumor necrosis factor inhibitors (TNFi) translate into differential mortality risks, as investigated in etanercept, infliximab, and adalimumab.METHODS: Data on patients with rheumatoid arthritis (RA) identified in the Swedish Biologics Register (Anti-Rheumatic Therapy in Sweden [ARTIS]) in whom first-ever treatment with a biologic agent (etanercept [n = 2,686], infliximab [n = 2,027], or adalimumab [n = 1,609]) was initiated between 2003 and 2008 were linked to national Swedish registers to get information on deaths from any cause, demographic features, RA characteristics, comorbid conditions, and concurrent treatment at the start of TNFi treatment. Hazard ratios (HRs) were modeled using multivariable adjusted and weighted Cox models.RESULTS: During 19,118 person-years of followup, 211 patients died (3.3%; 1.1 deaths per 100 person-years); 85% of the deaths occurred among patients who had been exposed to only one TNFi. We found no statistically significant difference in overall mortality rates across the exposure groups, regardless of adjustment and modeling approach (for infliximab versus etanercept, HR 1.1 [95% confidence interval (95% CI) 0.7-1.7], and for adalimumab versus etanercept, HR 1.3 [95% CI 0.9-2.0]).CONCLUSION: Overall, we noted no statistically significant difference in mortality rates between the 3 TNF inhibitors under study. Further studies need to examine whether certain subsets of patients are at increased risk of death with specific TNFi.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Keyword
- Medical Science
- Medicinsk vetenskap
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Arthritis and Rheumatism (Search for host publication in LIBRIS)
To the university's database
- 40 of 47
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Simard, Julia F
- Neovius, Martin
- Askling, Johan
- Baecklund, Eva
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Rheumatology and ...
- Articles in the publication
- Arthritis and Rh ...
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
